227 related articles for article (PubMed ID: 16965411)
21. [Topical imiquimod as palliative therapy for extensive lentigo maligna on the cheek].
Cheikhrouhou H; Pouaha J; Claeys A; Truchetet F
Ann Dermatol Venereol; 2010 Feb; 137(2):142-4. PubMed ID: 20171439
[No Abstract] [Full Text] [Related]
22. Lentigo maligna successfully treated with imiquimod.
du Plessis PJ
S Afr J Surg; 2007 May; 45(2):72. PubMed ID: 17674567
[No Abstract] [Full Text] [Related]
23. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.
Powell AM; Russell-Jones R
J Am Acad Dermatol; 2004 May; 50(5):792-6. PubMed ID: 15097969
[TBL] [Abstract][Full Text] [Related]
24. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients.
Buettiker UV; Yawalkar NY; Braathen LR; Hunger RE
Arch Dermatol; 2008 Jul; 144(7):943-5. PubMed ID: 18645150
[No Abstract] [Full Text] [Related]
25. In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod.
Alarcon I; Carrera C; Alos L; Palou J; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Jul; 71(1):49-55. PubMed ID: 24725478
[TBL] [Abstract][Full Text] [Related]
26. Treatment of lentigo maligna with imiquimod before staged excision.
Cotter MA; McKenna JK; Bowen GM
Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of dermoscopy to monitor clinical efficacy of imiquimod treatment for lentigo maligna.
Micantonio T; Fargnoli MC; Peris K
Arch Dermatol; 2006 Apr; 142(4):530-1. PubMed ID: 16618884
[No Abstract] [Full Text] [Related]
28. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
29. Imiquimod as an antiaging agent.
Metcalf S; Crowson AN; Naylor M; Haque R; Cornelison R
J Am Acad Dermatol; 2007 Mar; 56(3):422-5. PubMed ID: 17184874
[TBL] [Abstract][Full Text] [Related]
30. Surgical treatments for lentigo maligna: a review.
McLeod M; Choudhary S; Giannakakis G; Nouri K
Dermatol Surg; 2011 Sep; 37(9):1210-28. PubMed ID: 21631635
[TBL] [Abstract][Full Text] [Related]
31. Topical imiquimod for periocular lentigo maligna.
Demirci H; Shields CL; Bianciotto CG; Shields JA
Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
[TBL] [Abstract][Full Text] [Related]
32. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
[TBL] [Abstract][Full Text] [Related]
33. Topical 5% imiquimod in the treatment of lentigo maligna.
Wong JG; Toole JW; Demers AA; Musto G; Wiseman MC
J Cutan Med Surg; 2012; 16(4):245-9. PubMed ID: 22784516
[TBL] [Abstract][Full Text] [Related]
34. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients.
Van Meurs T; Van Doorn R; Kirtschig G
Dermatol Surg; 2010 Jun; 36(6):853-8. PubMed ID: 20618370
[TBL] [Abstract][Full Text] [Related]
35. [Imiquimod treatment of lentigo maligna to dermoscopic and histologic clearance].
Lorentzen HF; Weismann K
Ugeskr Laeger; 2005 Sep; 167(39):3696-7. PubMed ID: 16219219
[TBL] [Abstract][Full Text] [Related]
36. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream.
van Meurs T; van Doorn R; Kirtschig G
Dermatol Surg; 2007 May; 33(5):623-6; discussion 626-7. PubMed ID: 17451589
[No Abstract] [Full Text] [Related]
37. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
[TBL] [Abstract][Full Text] [Related]
38. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):407-412. PubMed ID: 35431054
[TBL] [Abstract][Full Text] [Related]
39. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
Woodmansee CS; McCall MW
Dermatol Surg; 2009 Aug; 35(8):1286-9. PubMed ID: 19438661
[No Abstract] [Full Text] [Related]
40. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.
Kirtschig G; van Meurs T; van Doorn R
Acta Derm Venereol; 2015 Jan; 95(1):83-5. PubMed ID: 24696093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
